Literature DB >> 21705143

Activation of spinal extracellular signal-regulated kinases (ERK) 1/2 is associated with the development of visceral hyperalgesia of the bladder.

H Henry Lai1, Chang-Shen Qiu, Lara W Crock, Maria Elena P Morales, Timothy J Ness, Robert W Gereau.   

Abstract

Activation of extracellular signal-regulated kinases (ERK) 1/2 in dorsal horn neurons is important for the development of somatic hypersensitivity and spinal central sensitization after peripheral inflammation. However, data regarding the roles of spinal ERK1/2 in the development of visceral hyperalgesia are sparse. Here we studied the activation of ERK1/2 in the lumbosacral spinal cord after innocuous and noxious distention of the inflamed (cyclophosphamide-treated) and noninflamed urinary bladder in mice. We also correlated the spinal ERK1/2 activation to distention-evoked bladder nociception as quantified by the abdominal visceromotor response (VMR). Cyclophosphamide treatment (bladder inflammation) evoked increased bladder hyperalgesia and allodynia to bladder distention, as evident from an upward and leftward shift of the VMR stimulus-response curve compared with that of noninflamed mice. Development of bladder hyperalgesia was associated with robust enhancement of ERK1/2 activation in the dorsal horn and deeper laminae bilaterally in the L6-S1 spinal cord. Functional blockade of spinal ERK1/2 activity via intrathecal administration of the upstream MEK inhibitor U0126 attenuated distention-evoked bladder nociception and caused a significant downward shift of the VMR stimulus-response curve. In summary, we have provided functional and immunohistochemical evidence that activation of lumbosacral spinal ERK1/2 is associated with the development of primary visceral (bladder) hyperalgesia. Our results suggest that aberrant processing of visceral nociceptive information at the level of the lumbosacral spinal cord via activation of ERK1/2 signaling may contribute to chronic bladder pain in the context of inflammation. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21705143      PMCID: PMC3157542          DOI: 10.1016/j.pain.2011.05.017

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  41 in total

1.  The A-type potassium channel Kv4.2 is a substrate for the mitogen-activated protein kinase ERK.

Authors:  J P Adams; A E Anderson; A W Varga; K T Dineley; R G Cook; P J Pfaffinger; J D Sweatt
Journal:  J Neurochem       Date:  2000-12       Impact factor: 5.372

2.  Metabotropic glutamate receptor subtypes 1 and 5 are activators of extracellular signal-regulated kinase signaling required for inflammatory pain in mice.

Authors:  F Karim; C C Wang; R W Gereau
Journal:  J Neurosci       Date:  2001-06-01       Impact factor: 6.167

3.  Region-specific changes in the phosphorylation of ERK1/2 and ERK5 in rat micturition pathways following cyclophosphamide-induced cystitis.

Authors:  Li-Ya Qiao; Melisa A Gulick
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-11-16       Impact factor: 3.619

4.  The role of metabotropic glutamate receptor mGlu5 in control of micturition and bladder nociception.

Authors:  Youmin Hu; Li Dong; Biying Sun; Marlene A Guillon; Leah R Burbach; Philip A Nunn; Xingrong Liu; Olga Vilenski; Anthony P D W Ford; Yu Zhong; Weifang Rong
Journal:  Neurosci Lett       Date:  2008-11-14       Impact factor: 3.046

5.  Immunohistochemistry of synaptic input and functional characterizations of neurons near the spinal central canal.

Authors:  C N Honda; C L Lee
Journal:  Brain Res       Date:  1985-09-16       Impact factor: 3.252

Review 6.  The MAPK signaling cascade.

Authors:  R Seger; E G Krebs
Journal:  FASEB J       Date:  1995-06       Impact factor: 5.191

7.  The distribution of visceral primary afferents from the pelvic nerve to Lissauer's tract and the spinal gray matter and its relationship to the sacral parasympathetic nucleus.

Authors:  C Morgan; I Nadelhaft; W C de Groat
Journal:  J Comp Neurol       Date:  1981-09-20       Impact factor: 3.215

8.  Phosphorylation of extracellular signal-regulated kinases in urinary bladder in rats with cyclophosphamide-induced cystitis.

Authors:  Kimberly A Corrow; Margaret A Vizzard
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-04-04       Impact factor: 3.619

9.  Activation of spinal extracellular signaling-regulated kinase-1 and -2 by intraplantar carrageenan in rodents.

Authors:  Alba Galan; J Antonio Lopez-Garcia; Fernando Cervero; Jennifer M A Laird
Journal:  Neurosci Lett       Date:  2002-03-29       Impact factor: 3.046

10.  Extracellular signaling-regulated kinase-1 and -2 (ERK 1/2) mediate referred hyperalgesia in a murine model of visceral pain.

Authors:  Alba Galan; Fernando Cervero; Jennifer M A Laird
Journal:  Brain Res Mol Brain Res       Date:  2003-08-19
View more
  30 in total

1.  Serotonergic paraneurones in the female mouse urethral epithelium and their potential role in peripheral sensory information processing.

Authors:  F A Kullmann; H H Chang; C Gauthier; B M McDonnell; J-C Yeh; D R Clayton; A J Kanai; W C de Groat; G L Apodaca; L A Birder
Journal:  Acta Physiol (Oxf)       Date:  2017-08-08       Impact factor: 6.311

2.  Activation of membrane estrogen receptors attenuates opioid receptor-like1 receptor-mediated antinociception via an ERK-dependent non-genomic mechanism.

Authors:  K M Small; S Nag; S S Mokha
Journal:  Neuroscience       Date:  2013-10-24       Impact factor: 3.590

Review 3.  Urologic chronic pelvic pain syndrome: insights from the MAPP Research Network.

Authors:  J Quentin Clemens; Chris Mullins; A Lenore Ackerman; Tamara Bavendam; Adrie van Bokhoven; Benjamin M Ellingson; Steven E Harte; Jason J Kutch; H Henry Lai; Katherine T Martucci; Robert Moldwin; Bruce D Naliboff; Michel A Pontari; Siobhan Sutcliffe; J Richard Landis
Journal:  Nat Rev Urol       Date:  2019-03       Impact factor: 14.432

4.  Central amygdala metabotropic glutamate receptor 5 in the modulation of visceral pain.

Authors:  Lara W Crock; Benedict J Kolber; Clinton D Morgan; Katelyn E Sadler; Sherri K Vogt; Michael R Bruchas; Robert W Gereau
Journal:  J Neurosci       Date:  2012-10-10       Impact factor: 6.167

5.  Artemin Immunotherapy Is Effective in Preventing and Reversing Cystitis-Induced Bladder Hyperalgesia via TRPA1 Regulation.

Authors:  Jennifer J DeBerry; Jami L Saloman; Brian K Dragoo; Kathryn M Albers; Brian M Davis
Journal:  J Pain       Date:  2015-04-17       Impact factor: 5.820

6.  Segmental hyperalgesia to mechanical stimulus in interstitial cystitis/bladder pain syndrome: evidence of central sensitization.

Authors:  H Henry Lai; Vivien Gardner; Timothy J Ness; Robert W Gereau
Journal:  J Urol       Date:  2013-12-06       Impact factor: 7.450

7.  Anti-vascular endothelial growth factor treatment decreases bladder pain in cyclophosphamide cystitis: a Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network animal model study.

Authors:  H Henry Lai; Baixin Shen; Pooja Vijairania; Xiaowei Zhang; Sherri K Vogt; Robert W Gereau
Journal:  BJU Int       Date:  2017-06-29       Impact factor: 5.588

Review 8.  Mechanisms of pain from urinary tract infection.

Authors:  John M Rosen; David J Klumpp
Journal:  Int J Urol       Date:  2014-04       Impact factor: 3.369

9.  TLR4 upregulates CBS expression through NF-κB activation in a rat model of irritable bowel syndrome with chronic visceral hypersensitivity.

Authors:  Bo Yuan; Wei-Hong Tang; Li-Juan Lu; Yuan Zhou; Hong-Yan Zhu; You-Lang Zhou; Hong-Hong Zhang; Chuang-Ying Hu; Guang-Yin Xu
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

10.  Up-regulation of brain-derived neurotrophic factor is regulated by extracellular signal-regulated protein kinase 5 and by nerve growth factor retrograde signaling in colonic afferent neurons in colitis.

Authors:  Sharon J Yu; John R Grider; Melisa A Gulick; Chun-mei Xia; Shanwei Shen; Li-Ya Qiao
Journal:  Exp Neurol       Date:  2012-08-19       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.